Portola Pharmaceuticals (Nasdaq: PTLA) is a leading biopharmaceutical company, providing medicines for the treatment of thrombosis, inflammation, and hematologic disorders. It is presently involved in getting approvals for their products Betrixaban for the treatment of life-threatening thrombosis, Andexanet Alfa for reversing anti-coagulant activity with FXa inhibitor and Cerdulatinib for the treatment of hematologic cancers.
Portola Pharmaceuticals was formed in 2003 in South San Francisco, California. It now has employee strength of 150 and went public in 2013. The company grew by raising money through private and public funding to the extent of $450mn including a $100mn Initial Public Offering IPO in 2013.